Recent progress of dendritic cell-derived exosomes in tumor immunotherapy
Investigational New Drugs · 2026-04 · 44 (2) · 196-210
DOI: 10.1007/s10637-026-01604-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Investigational New Drugs, online erschienen am 09.04.2026. Verfasst von Baiyan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengzhou, 450046, China. Hauptthemen laut MEDLINE: Exosomes, Dendritic Cells, Immunotherapy, Neoplasms. Die Arbeit nennt 108 Literaturangaben. Gefördert von: Key ScientifcResearch Projects of Colleges and Universities in Henan Province, Special Project of Basic Research of Key ScientifcResearch Projects of Colleges and Universities in Henan Province, Henan Province Science and Technology Research and Development Plan Joint Fund (Superior discipline Cultivation).
Abstract (Originalsprache)
Despite advancements in conventional tumor therapies including surgery and chemotherapy, effective cancer management remains challenging due to treatment resistance and tumor microenvironment complexity. Dendritic cell (DC)-based vaccines, while representing a milestone in tumor immunotherapy, face clinical limitations such as poor viability and limited antigen presentation capacity. Importantly, dendritic cell-derived exosomes (DEXs) have emerged as a potential alternative. In contrast to DC vaccines, DEXs possess excellent in vivo biocompatibility and biosafety, demonstrate higher immunogenicity, exhibit stronger immunosuppressive resistance, and require lower production costs. Mechanistically, DEXs overcome immunosuppressive obstacles through dual delivery of immunostimulatory cargo and tumor-associated antigens, thereby achieving superior anti-tumor effects. This review examines recent research progress regarding DEXs in tumor immunotherapy, with particular emphasis on their roles in immune activation, the regulation of the tumor microenvironment, serving as drug delivery vehicles, and vaccine development. These advancements will help deepen the understanding of tumor immunotherapy and promote clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical College, Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengzhou, 450046, China.
- Henan Engineering Research Center for Chinese Medicine Foods for Special Medical Purpose, Zhengzhou, 450046, China.
- Medical College, Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengzhou, 450046, China. fsy@hactcm.edu.cn.
- Henan Engineering Research Center for Chinese Medicine Foods for Special Medical Purpose, Zhengzhou, 450046, China. fsy@hactcm.edu.cn.
Förderung
- Key ScientifcResearch Projects of Colleges and Universities in Henan Province
- Special Project of Basic Research of Key ScientifcResearch Projects of Colleges and Universities in Henan Province
- Henan Province Science and Technology Research and Development Plan Joint Fund (Superior discipline Cultivation)
- Science and Technology Key Project of Henan Province
Zitieren
APA
Wang, B., Hu, Y., Zhou, Y., Han, Q., Huang, Y., Dong, Y., Zhang, Y., Guo, Z., Zhang, X., & Feng, S. (2026). Recent progress of dendritic cell-derived exosomes in tumor immunotherapy. Investigational New Drugs, 44(2), 196-210. https://doi.org/10.1007/s10637-026-01604-4
Vancouver
Wang B, Hu Y, Zhou Y, Han Q, Huang Y, Dong Y, et al. Recent progress of dendritic cell-derived exosomes in tumor immunotherapy. Investigational New Drugs. 2026;44(2):196-210. doi:10.1007/s10637-026-01604-4
BibTeX
@article{Wang2026,
author = {Wang, Baiyan and Hu, Yirui and Zhou, Yujia and Han, Qianqian and Huang, Yu and Dong, Yuanhang and Zhang, Yike and Guo, Zixuan and Zhang, Xuan and Feng, Shuying},
title = {Recent progress of dendritic cell-derived exosomes in tumor immunotherapy},
journal = {Investigational New Drugs},
year = {2026},
volume = {44},
number = {2},
pages = {196--210},
doi = {10.1007/s10637-026-01604-4}
}
EUVIMED